Abera Bioscience AB (“Abera” or the “Company”) today announces that the Dutch regulatory authority, the Central Committee on Research Involving Human Subjects (CCMO), has approved

Abera Bioscience AB (“Abera” or the “Company”) today announces that a scientific article on the Company’s intranasal pneumococcal vaccine has been published in the journal

Abera Bioscience AB (”Abera” eller ”Bolaget”) meddelar idag att styrelsen beslutat att Bolaget ska övergå till redovisning enligt International Financial Reporting Standards (IFRS). Övergången är

Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT ANDRA KVARTALET 2026 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 1 563 (4 297) kSEK Resultatet efter finansiella poster

Abera Bioscience AB (“Abera” or the “Company”) today announces the outcome of the exercise of warrants of series TO2025/2026, which were issued in connection with

Abera Bioscience AB today announced that, together with its clinical partner Radboud University Medical Center (Radboud UMC), it has submitted a Clinical Trial Application to

Board member Mats Wahlström has, in consultation with the Board of Directors, decided to transfer his warrants of series TO2025/2026 to members of Abera Bioscience’s

Abera Bioscience today announced that the Company has completed a ferret study during the spring with its intranasal influenza vaccine candidate. The outcome of the

Abera Bioscience AB (“Abera” or the “Company”) today announced that a scientific article has been accepted for publication in the peer-reviewed journal Vaccine. The publication,

Abera Bioscience AB (“Abera” or the “Company”) today announces that CEPI (Coalition for Epidemic Preparedness Innovations) has decided to extend the ongoing project supporting the

Årsstämma 2026 i Abera Bioscience AB (”Abera” eller ”Bolaget”) hölls den 10 juni 2026. Ordförande Anders Ericson höll ett inledande anförande som också återfinnas längre

Abera Bioscience AB (“Abera” or the “Company”) today announces that GMP production of clinical trial material for the Company’s vaccine candidate Ab-01.12 – a first-in-class

Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT FÖRSTA KVARTALET 2026 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 3 553 (3 574) kSEK Resultatet efter finansiella poster

Abera Bioscience AB (publ) meddelar idag att bolaget publicerar årsredovisningen för 2025. Årsredovisning finns tillgänglig på bolagets hemsida under “Investors” samt via bifogad PDF: Abera

Kallelse till årsstämma i Abera Bioscience AB Aktieägarna i Abera Bioscience AB (publ), org. nr. 556909-0904 (”Bolaget”), kallas härmed till årsstämma onsdagen den 10 juni

Abera Bioscience AB (“Abera” or the “Company”) today announces that a scientific article has been published in the well-renowned journal npj Vaccines. The publication provides

Abera Bioscience publishes a video recording of the presentation given by CEO Maria Alriksson at Aktiespararna’s event “Stora Aktiedagarna” in Stockholm on Tuesday, March 10,

Abera Bioscience publicerar idag ett brev från bolagets nya huvudägare Göran Ofsén. Bolaget har fått flera frågor kring den nyemission som nyligen genomfördes där Göran

Abera Bioscience today announces that the Company is initiating additional preclinical studies within its influenza program, with a focus on pandemic avian influenza. The studies

Abera Bioscience AB (“Abera” or the “Company”), which develops innovative mucosal vaccines to prevent life-threatening diseases, today announces that its Board of Directors, based on

Abera Bioscience, which develops nasal vaccines based on its proprietary technology platform, is in an intensive development phase in which several vaccine candidates are being

Abera Bioscience AB (“Abera” or “the Company”) today presents new positive long-term data from a preclinical study of its nasal influenza vaccine candidate.
The results show

Abera Bioscience AB (“Abera” or the “Company”) has been awarded a £70,000 grant from BactiVac, the Bacterial Vaccines Network. The funding will support studies of

Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT ANDRA KVARTALET 2025 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 4 297 (4 506) kSEK Resultatet efter finansiella poster

Abera Bioscience AB (“Abera” or the “Company”) announces the outcome of the directed issue of units that was announced on 17 July 2025. The issue

Abera Bioscience AB (“Abera” or the “Company”) has been granted an additional approximately SEK 4.7 million (about USD 450,000) from CEPI (the Coalition for Epidemic

Abera Bioscience AB (“Abera” or the “Company”), which develops innovative mucosal vaccines to prevent life-threatening diseases, today announces that the Board of Directors has resolved,

The 2025 Annual General Meeting (AGM) of Abera Bioscience AB (“Abera” or “the Company”) was held on June 11, 2025. Chairman Anders Ericson delivered an